#1 Clinical Trials Search in Europe

Deflazacort

This article examines the use of deflazacort, a corticosteroid medication, in various clinical trials. Deflazacort has been studied primarily for treating Duchenne muscular dystrophy (DMD) and other muscular disorders, as well as conditions like allergic bronchopulmonary aspergillosis. The trials aim to evaluate the safety, efficacy, and pharmacokinetics of deflazacort across different patient populations and dosing regimens.

Table of Contents

What is Deflazacort?

Deflazacort is a type of medication known as a glucocorticoid, which belongs to a larger group of drugs called corticosteroids. It is also referred to by its brand name Emflaza® or abbreviated as DFZ[1][2]. Deflazacort is a synthetic (man-made) version of hormones that are naturally produced by the adrenal glands in our bodies. It has powerful anti-inflammatory and immunosuppressive effects, meaning it can reduce inflammation and suppress the body’s immune response[3].

Interestingly, deflazacort is what’s called a “prodrug.” This means that when you take it, your body converts it into an active form called 21-desacetyl deflazacort. This active form is what actually provides the therapeutic effects in your body[3].

Conditions Treated with Deflazacort

Deflazacort is used to treat several conditions, but it’s most commonly studied and used for:

  • Duchenne Muscular Dystrophy (DMD): This is a genetic disorder characterized by progressive muscle degeneration and weakness. Deflazacort is approved for use in DMD patients aged 2 years and older[4].
  • Limb-Girdle Muscular Dystrophy (LGMD): This is a group of rare genetic diseases that cause weakness and wasting of the voluntary muscles in the arms and legs[5].
  • Allergic Bronchopulmonary Aspergillosis (ABPA): This is a condition where the lungs become inflamed due to an allergic reaction to a type of fungus called Aspergillus[6].
  • Dysferlinopathies: These are a group of rare genetic muscle disorders, including a type of limb-girdle muscular dystrophy (LGMD2B) and Miyoshi myopathy[7].

How Deflazacort Works

Deflazacort works by mimicking the effects of hormones produced naturally by your adrenal glands. These hormones help to control many important functions in the body, including the immune system’s response to inflammation.

In conditions like Duchenne muscular dystrophy, deflazacort is believed to work by:

  • Reducing inflammation: It helps to decrease the ongoing inflammation in muscles, which can slow down muscle damage.
  • Stabilizing cell membranes: It may help to strengthen the outer layer of muscle cells, making them more resistant to damage.
  • Suppressing the immune system: In some conditions, the immune system may inadvertently contribute to muscle damage. Deflazacort can help to reduce this effect[7].

How Deflazacort is Administered

Deflazacort is typically taken orally (by mouth) in the form of tablets. The dosage can vary depending on the condition being treated and the individual patient. Here are some general guidelines:

  • For Duchenne muscular dystrophy, a common dose is 0.9 milligrams per kilogram of body weight (mg/kg) taken once daily[4].
  • In some studies for limb-girdle muscular dystrophy, a dose of 0.6 mg/kg/day was used[5].
  • The medication is usually taken in the morning with food to help reduce stomach upset[8].

It’s important to note that the exact dosage and schedule should always be determined by your healthcare provider based on your specific condition and needs.

Clinical Studies on Deflazacort

Numerous clinical studies have been conducted to evaluate the effectiveness and safety of deflazacort for various conditions. Here are some key findings:

  • Duchenne Muscular Dystrophy (DMD): Studies have shown that deflazacort can help improve muscle strength and function in children with DMD. Researchers have looked at outcomes such as the time it takes to climb stairs, walk or run 10 meters, and overall muscle strength[4].
  • Limb-Girdle Muscular Dystrophy (LGMD): A study is ongoing to evaluate how deflazacort affects muscle function in people with LGMD. Researchers are measuring changes in tasks like climbing stairs, walking for two minutes, and overall muscle strength[5].
  • Allergic Bronchopulmonary Aspergillosis (ABPA): A study is comparing deflazacort to another steroid (prednisolone) in treating ABPA. They’re looking at factors like changes in weight and improvements in lung function[6].

Potential Side Effects

Like all medications, deflazacort can cause side effects. It’s important to discuss these potential risks with your healthcare provider. Some possible side effects include:

  • Weight gain: This is one of the most common side effects, particularly with long-term use.
  • Changes in behavior or mood: Some patients may experience mood swings or behavioral changes.
  • Increased risk of infections: Because deflazacort suppresses the immune system, it can make you more susceptible to infections.
  • Changes in blood sugar levels: Deflazacort can affect how your body processes sugar, which is particularly important for people with diabetes.
  • Bone density changes: Long-term use may affect bone density, potentially increasing the risk of osteoporosis.
  • Growth suppression in children: When used long-term in children, it may affect growth rate[4][2].

Special Considerations

There are some important things to keep in mind when taking deflazacort:

  • Long-term use: Deflazacort is often used as a long-term treatment, especially for conditions like Duchenne muscular dystrophy. Your doctor will carefully monitor you for any side effects over time.
  • Dosage adjustments: The dose of deflazacort may need to be adjusted if you have liver or kidney problems[2][3].
  • Food interactions: Some studies have looked at how food affects how deflazacort is absorbed by the body. Always take deflazacort as directed by your healthcare provider[8].
  • Gradual discontinuation: If you’ve been taking deflazacort for a long time, don’t stop taking it suddenly. Your doctor will provide a schedule to gradually reduce your dose.

Remember, while this information provides a general overview, it’s crucial to consult with your healthcare provider for personalized advice and information about deflazacort and its use in your specific condition.

Aspect Details
Primary Conditions Studied Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD), Allergic Bronchopulmonary Aspergillosis (ABPA)
Common Dosages 0.45 mg/kg/day to 0.9 mg/kg/day, orally
Main Outcome Measures Safety (adverse events, vital signs, lab tests), Efficacy (muscle function, lung function), Pharmacokinetics
Study Durations Range from single-dose studies to 52-week trials and longer extension studies
Patient Populations Children, adolescents, and adults with muscular dystrophies; patients with renal or hepatic impairment; healthy volunteers
Potential Advantages May have fewer side effects compared to other corticosteroids, particularly in terms of weight gain and bone density loss
Areas of Investigation Efficacy in treating muscular dystrophies, safety profile, effects of food on absorption, use in patients with organ impairment

FAQ

  • What is deflazacort and what is it used to treat? Deflazacort is a glucocorticoid medication with anti-inflammatory and immunosuppressive effects. It is primarily being studied as a treatment for Duchenne muscular dystrophy (DMD) and other muscular disorders. It's also being investigated for conditions like allergic bronchopulmonary aspergillosis.
  • How is deflazacort administered in clinical trials? In most trials, deflazacort is given orally as tablets. The dosage varies depending on the study, but common doses range from 0.45 mg/kg/day to 0.9 mg/kg/day. Some trials also examine crushed tablets mixed with applesauce or as an oral suspension.
  • What are the main outcomes being measured in deflazacort trials? The trials typically measure safety outcomes like adverse events, changes in vital signs, and laboratory tests. Efficacy outcomes often include changes in muscle function tests, lung function, and disease-specific measures. Some trials also examine the pharmacokinetics of deflazacort, looking at how the drug is absorbed, distributed, and eliminated from the body.
  • Are there any potential side effects of deflazacort? Like other corticosteroids, deflazacort can have side effects. These may include weight gain, cushingoid features (round face, acne, etc.), increased blood pressure, hyperglycemia, and bone density changes. However, some studies suggest deflazacort may have fewer side effects compared to other corticosteroids like prednisolone.
  • How long do the clinical trials for deflazacort typically last? The duration of deflazacort trials varies widely. Some pharmacokinetic studies last only a few days, while others examining long-term safety and efficacy can last up to 52 weeks or even longer in extension studies. The length often depends on the specific goals of each trial and the condition being studied.

Ongoing Clinical Trials on Deflazacort

  • Study on the Long-Term Safety of Dazukibart in Patients with Idiopathic Inflammatory Myopathies, Including Dermatomyositis and Polymyositis

    Recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria Hungary Italy Poland Spain Sweden

  • Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Hungary Italy +4

  • Study on the Effectiveness of Deflazacort in Treating LMNA-related Congenital Muscular Dystrophy in Adults and Children

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Duchenne muscular dystrophy (DMD): A genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Corticosteroid: A class of steroid hormones that reduce inflammation in the body and affect the immune system.
  • Limb-Girdle Muscular Dystrophy (LGMD): A group of rare genetic diseases that cause weakness and wasting of the muscles in the arms and legs.
  • Forced Vital Capacity (FVC): The amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Bioavailability: The proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an active effect.
  • End-Stage Renal Disease (ESRD): The last stage of chronic kidney disease where the kidneys are functioning below 10-15% of their normal capacity.
  • Child-Pugh classification: A scoring system used to assess the prognosis of chronic liver disease, mainly cirrhosis.
  • Allergic Bronchopulmonary Aspergillosis (ABPA): A condition characterized by an allergic reaction to the fungus Aspergillus, primarily affecting people with asthma or cystic fibrosis.

References

  1. https://clinicaltrials.gov/study/NCT02251600
  2. https://clinicaltrials.gov/study/NCT02286622
  3. https://clinicaltrials.gov/study/NCT02286609
  4. https://clinicaltrials.gov/study/NCT03642145
  5. https://clinicaltrials.gov/study/NCT03783923
  6. https://clinicaltrials.gov/study/NCT04227483
  7. https://clinicaltrials.gov/study/NCT00527228
  8. https://clinicaltrials.gov/study/NCT02485431